• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.

作者信息

Charness Michael E, Gupta Kalpana, Stack Gary, Strymish Judith, Adams Eleanor, Lindy David C, Mohri Hiroshi, Ho David D

机构信息

VA Boston Healthcare System, West Roxbury, MA

VA Connecticut Healthcare System, West Haven, CT.

出版信息

N Engl J Med. 2022 Sep 15;387(11):1045-1047. doi: 10.1056/NEJMc2206449. Epub 2022 Sep 7.

DOI:10.1056/NEJMc2206449
PMID:36069968
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9511633/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90da/9511633/4989418b42df/NEJMc2206449_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90da/9511633/4989418b42df/NEJMc2206449_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90da/9511633/4989418b42df/NEJMc2206449_f1.jpg

相似文献

1
Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.奈玛特韦-利托那韦治疗后新型冠状病毒2型感染的反弹
N Engl J Med. 2022 Sep 15;387(11):1045-1047. doi: 10.1056/NEJMc2206449. Epub 2022 Sep 7.
2
Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.奈玛特韦-利托那韦与新冠病毒感染中的病毒载量反弹
N Engl J Med. 2022 Sep 15;387(11):1047-1049. doi: 10.1056/NEJMc2205944. Epub 2022 Sep 7.
3
Paxlovid for treatment of COVID-19.用于治疗新冠病毒病的帕罗韦德
Med Lett Drugs Ther. 2022 Jan 24;64(1642):9-10.
4
From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.从阳性到阴性再到阳性——服用帕罗韦德的部分新冠患者病情反弹之谜
JAMA. 2022 Jun 28;327(24):2380-2382. doi: 10.1001/jama.2022.9925.
5
Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare.帕罗韦德治疗后再住院、急诊就诊情况罕见。
JAMA. 2022 Jul 26;328(4):323. doi: 10.1001/jama.2022.11942.
6
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
7
Nirmatrelvir-ritonavir for COVID-19.用于治疗新冠肺炎的奈玛特韦片/利托那韦片组合包装
CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.
8
Antiviral pills could change pandemic's course.抗病毒药丸可能会改变疫情的走向。
Science. 2021 Nov 12;374(6569):799-800. doi: 10.1126/science.acx9605. Epub 2021 Nov 11.
9
Treatment of COVID-19 in high-risk outpatients.高危门诊患者的新冠病毒病治疗
Med Lett Drugs Ther. 2022 Feb 7;64(1643):e1.
10
Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.尼马曲韦-利托那韦与其他抗病毒药物治疗 COVID-19 患者的比较：系统评价和荟萃分析。
J Med Virol. 2023 Apr;95(4):e28732. doi: 10.1002/jmv.28732.

引用本文的文献

1
Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir.使用瑞德西韦治疗后COVID-19症状反弹的发生率。
Infect Dis Rep. 2025 May 1;17(3):43. doi: 10.3390/idr17030043.
2
Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study.新冠病毒感染患者中口服阿兹夫定与奈玛特韦-利托那韦的复合结局：一项回顾性队列研究
Front Pharmacol. 2025 Apr 4;16:1546787. doi: 10.3389/fphar.2025.1546787. eCollection 2025.
3
Combination therapy enhances the antiviral activity of IFN-λ against SARS-CoV-2 and MERS-CoV.

本文引用的文献

1
Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).新型冠状病毒病 2019（COVID-19）经奈玛特韦-利托那韦治疗后病毒学反弹的特征。
Clin Infect Dis. 2023 Feb 8;76(3):e526-e529. doi: 10.1093/cid/ciac512.
2
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
联合疗法增强了干扰素-λ对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和中东呼吸综合征冠状病毒（MERS-CoV）的抗病毒活性。
Virus Res. 2025 May;355:199560. doi: 10.1016/j.virusres.2025.199560. Epub 2025 Mar 18.
4
Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2.新型冠状病毒感染的肺移植受者使用奈玛特韦/利托那韦后的病毒反弹及安全性
Biosaf Health. 2023 Sep 2;5(5):266-271. doi: 10.1016/j.bsheal.2023.08.004. eCollection 2023 Oct.
5
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.模型表明，奈玛特韦-利托那韦治疗后SARS-CoV-2的反弹是由靶细胞保留以及病毒清除不完全共同驱动的。
J Virol. 2025 Mar 18;99(3):e0162324. doi: 10.1128/jvi.01623-24. Epub 2025 Feb 4.
6
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.严重急性呼吸综合征冠状病毒2的进化：对诊断、治疗、疫苗有效性及研发的影响
Vaccines (Basel). 2024 Dec 28;13(1):17. doi: 10.3390/vaccines13010017.
7
Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis.抗病毒药物和单克隆抗体治疗感染奥密克戎变异株的COVID-19患者的比较疗效：一项系统评价和网状Meta分析
Influenza Other Respir Viruses. 2024 Dec;18(12):e70065. doi: 10.1111/irv.70065.
8
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.在一项随机安慰剂对照试验中，抗严重急性呼吸综合征冠状病毒2单克隆抗体治疗后的病毒和症状反弹
J Infect Dis. 2025 Feb 4;231(1):131-136. doi: 10.1093/infdis/jiae501.
9
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.模型显示，奈玛特韦-利托那韦治疗后SARS-CoV-2反弹是由靶细胞保留以及病毒清除不完全共同驱动的。
bioRxiv. 2024 Sep 16:2024.09.13.613000. doi: 10.1101/2024.09.13.613000.
10
A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases.关于尼马曲韦/利托那韦相关复阳 COVID-19 的一份超声报告：利用新数据库评估新发疾病。
PLoS One. 2024 Sep 25;19(9):e0308205. doi: 10.1371/journal.pone.0308205. eCollection 2024.